RAFAEL HOLDINGS, INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
RAFAEL HOLDINGS, INC. (RFL) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of -$17.72 million for the 12-month period ending 2022-07-31, per its 10-K filed 2022-10-31.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2022-10-31
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2022 was -$17.72M.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2021 was -$222.00K.
- RAFAEL HOLDINGS, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2020 was -$338.00K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|
| 2022-07-31 | -$17.72M 10-K · filed 2022-10-31 |
| 2021-07-31 | -$222.00K 10-K · filed 2022-10-31 |
| 2020-07-31 | -$338.00K 10-K · filed 2021-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |